388 related articles for article (PubMed ID: 21346614)
21. Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.
Humble MB; Uvnäs-Moberg K; Engström I; Bejerot S
BMC Psychiatry; 2013 Dec; 13():344. PubMed ID: 24359174
[TBL] [Abstract][Full Text] [Related]
22. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).
Haghighi M; Jahangard L; Mohammad-Beigi H; Bajoghli H; Hafezian H; Rahimi A; Afshar H; Holsboer-Trachsler E; Brand S
Psychopharmacology (Berl); 2013 Aug; 228(4):633-40. PubMed ID: 23525525
[TBL] [Abstract][Full Text] [Related]
23. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
Pigott TA; Seay SM
J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
[TBL] [Abstract][Full Text] [Related]
24. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.
Kordon A; Wahl K; Koch N; Zurowski B; Anlauf M; Vielhaber K; Kahl KG; Broocks A; Voderholzer U; Hohagen F
J Clin Psychopharmacol; 2008 Oct; 28(5):550-4. PubMed ID: 18794652
[TBL] [Abstract][Full Text] [Related]
25. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder.
Friedman S; Abdallah TA; Oumaya M; Rouillon F; Guelfi JD
J Clin Psychiatry; 2007 Jun; 68(6):972-3. PubMed ID: 17592930
[No Abstract] [Full Text] [Related]
26. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.
Simpson HB; Foa EB; Liebowitz MR; Ledley DR; Huppert JD; Cahill S; Vermes D; Schmidt AB; Hembree E; Franklin M; Campeas R; Hahn CG; Petkova E
Am J Psychiatry; 2008 May; 165(5):621-30. PubMed ID: 18316422
[TBL] [Abstract][Full Text] [Related]
27. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
28. Intravenous Clomipramine for Treatment-Resistant Obsessive-Compulsive Disorder.
Karameh WK; Khani M
Int J Neuropsychopharmacol; 2015 Jul; 19(2):. PubMed ID: 26221004
[TBL] [Abstract][Full Text] [Related]
29. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
[TBL] [Abstract][Full Text] [Related]
30. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
Denys D; de Geus F; van Megen HJ; Westenberg HG
J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
[TBL] [Abstract][Full Text] [Related]
31. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.
Foa EB; Liebowitz MR; Kozak MJ; Davies S; Campeas R; Franklin ME; Huppert JD; Kjernisted K; Rowan V; Schmidt AB; Simpson HB; Tu X
Am J Psychiatry; 2005 Jan; 162(1):151-61. PubMed ID: 15625214
[TBL] [Abstract][Full Text] [Related]
32. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study.
Feng B; Zhang ZJ; Zhu RM; Yuan GZ; Luo LY; McAlonan GM; Xu FZ; Chen J; Liu LY; Lv YY; Wong HK; Zhang Y; Zhu LX
J Psychiatr Res; 2016 Sep; 80():30-37. PubMed ID: 27281260
[TBL] [Abstract][Full Text] [Related]
33. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?
Carey PD; Lochner C; Kidd M; Van Ameringen M; Stein DJ; Denys D
Int Clin Psychopharmacol; 2012 Nov; 27(6):321-5. PubMed ID: 22859064
[TBL] [Abstract][Full Text] [Related]
34. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial.
Noorbala AA; Hosseini SH; Mohammadi MR; Akhondzadeh S
J Clin Pharm Ther; 1998 Apr; 23(2):155-9. PubMed ID: 9786103
[TBL] [Abstract][Full Text] [Related]
35. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
[TBL] [Abstract][Full Text] [Related]
36. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study.
Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E
J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050
[TBL] [Abstract][Full Text] [Related]
37. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
Koran LM; Aboujaoude E; Gamel NN
J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review.
Piccinelli M; Pini S; Bellantuono C; Wilkinson G
Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913
[TBL] [Abstract][Full Text] [Related]
39. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
[TBL] [Abstract][Full Text] [Related]
40. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
Masi G; Pfanner C; Millepiedi S; Berloffa S
J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]